Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab Monotherapy in Pediatric Peanut Allergy
NCT03793608Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2019
- Primary completion
- Feb 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of dupilumab in peanut allergy, sponsored by Regeneron Pharmaceuticals. Primary endpoint: Percentage of Participants Treated With Dupilumab Who Passed a DBPCFC With at Least 444 mg (Cumulative) Peanut Protein at Week 24. Started Mar 2019; status: completed.
02
Drugs
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT03793608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03793608.